Halozyme Therapeutics (HALO) Inventory (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Inventory data on file, last reported at $155.5 million in Q1 2026.

• On a quarterly basis, Inventory fell 5.7% year-over-year to $155.5 million in Q1 2026; TTM through Mar 2026 was $155.5 million, a 5.7% decrease from a year earlier, with the FY2025 full-year figure at $176.5 million, up 24.4% from the prior year.
• Inventory for Q1 2026 stood at $155.5 million, down from $176.5 million in the prior quarter.
• Over the last five years, Inventory for HALO reached as high as $185.8 million in Q3 2025 and fell as low as $47.8 million in Q1 2022.
• Historically, Inventory has averaged $135.9 million across 5 years, with a median of $132.4 million in 2023.
• Across the five-year window, Inventory retreated 18.14% in 2022 and surged 125.12% in 2023, its largest moves.
• Year by year, Inventory stood at $100.1 million in 2022, then gained by 27.44% to $127.6 million in 2023, then rose by 11.17% to $141.9 million in 2024, then climbed by 24.4% to $176.5 million in 2025, then dropped by 11.9% to $155.5 million in 2026.
• Per Business Quant data, the three most recent Inventory figures were $155.5 million in Q1 2026, $176.5 million in Q4 2025, and $185.8 million in Q3 2025.